FDA UNTITLED_LETTER - Wickliffe Pharmaceutical Inc - September 07, 2023

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Record Details

This UNTITLED LETTER record concerns Wickliffe Pharmaceutical Inc, with an inspection on September 7, 2023, issued by the Division of Pharmaceutical Quality Operations I, covering drugs.

Company: Wickliffe Pharmaceutical Inc
Inspection Date: September 7, 2023
Product Type: Drugs
Office: Division of Pharmaceutical Quality Operations I
People: Rebecca E. Dowd (Director of Investigations Branch)
Nicholas R. Kirkpatrick
Brian W. Garthwaite

Open in Dashboard

ID · 2a133e07-0650-4846-9910-fe6b849886c9

Violation Codes10

21 CFR 211.100(a)21 CFR 211.113(b)FD&C Act 501(a)(2)(B)FD&C Act 360b(a)(4)21 U.S.C. 360b21 CFR 211.6721 CFR 211.165(a)21 CFR 21021 U.S.C. 352(f)(1)21 CFR 530

Full citation text and observation details available on the Dashboard.